Safe engineering of cancer-associated fibroblasts enhances checkpoint blockade immunotherapy. 2023

Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.

Abundant cancer-associated fibroblasts (CAFs) in highly fibrotic breast cancer constitute an immunosuppressive barrier for T cell activity and are closely related to the failure of immune checkpoint blockade therapy (ICB). Inspired by the similar antigen-processing capacity of CAFs to professional antigen-presenting cells (APCs), a "turning foes to friends" strategy is proposed by in situ engineering immune-suppressed CAFs into immune-activated APCs for improving response rates of ICB. To achieve safe and specific CAFs engineering in vivo, a thermochromic spatiotemporal photo-controlled gene expression nanosystem was developed by self-assembly of molten eutectic mixture, chitosan andfusion plasmid. After photoactivatable gene expression, CAFs could be engineered as APCs via co-stimulatory molecule (CD86) expression, which effectively induced activation and proliferation of antigen-specific CD8 + T cells. Meanwhile, engineered CAFs could also secrete PD-L1 trap protein in situ for ICB, avoiding potential autoimmune-like disorders caused by "off-target" effects of clinically applied PD-L1 antibody. The study demonstrated that the designed nanosystem could efficiently engineer CAFs, significantly enhance the percentages of CD8+ T cells (4-folds), result in about 85% tumor inhibition rate and 83.3% survival rate at 60 days in highly fibrotic breast cancer, further inducing long-term immune memory effects and effectively inhibiting lung metastasis.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072645 Cancer-Associated Fibroblasts Subpopulation of heterogeneous fibroblasts within the TUMOR MICROENVIRONMENT that support NEOPLASTIC CELL TRANSFORMATION and NEOPLASTIC PROCESSES. Cancer Associated Fibroblasts,Tumor-Associated Fibroblasts,Cancer Associated Fibroblast,Cancer-Associated Fibroblast,Fibroblast, Cancer Associated,Fibroblast, Cancer-Associated,Fibroblast, Tumor-Associated,Fibroblasts, Cancer Associated,Fibroblasts, Cancer-Associated,Fibroblasts, Tumor-Associated,Tumor Associated Fibroblasts,Tumor-Associated Fibroblast
D000082082 Immune Checkpoint Inhibitors Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. CTLA-4 Inhibitor,CTLA-4 Inhibitors,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors,Immune Checkpoint Blockade,Immune Checkpoint Blockers,Immune Checkpoint Inhibition,Immune Checkpoint Inhibitor,PD-1 Inhibitor,PD-1 Inhibitors,PD-1-PD-L1 Blockade,PD-L1 Inhibitor,PD-L1 Inhibitors,Programmed Cell Death Protein 1 Inhibitor,Programmed Cell Death Protein 1 Inhibitors,Programmed Death-Ligand 1 Inhibitors,Blockade, PD-1-PD-L1,CTLA 4 Inhibitor,CTLA 4 Inhibitors,Checkpoint Blockade, Immune,Checkpoint Blockers, Immune,Checkpoint Inhibition, Immune,Checkpoint Inhibitor, Immune,Checkpoint Inhibitors, Immune,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors,Inhibitor, PD-1,PD 1 Inhibitor,PD 1 Inhibitors,PD 1 PD L1 Blockade,PD L1 Inhibitor,PD L1 Inhibitors,Programmed Death Ligand 1 Inhibitors
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments
D060890 B7-H1 Antigen An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION. Antigens, CD274,PD-L1 Protein,Programmed Cell Death 1 Ligand 1 Protein,Programmed Death Ligand 1,B7-H1 Immune Costimulatory Protein,B7H1 Immune Costimulatory Protein,CD274 Antigen,PD-L1 Costimulatory Protein,Programmed Cell Death 1 Ligand 1,Antigen, B7-H1,Antigen, CD274,B7 H1 Antigen,B7 H1 Immune Costimulatory Protein,CD274 Antigens,Costimulatory Protein, PD-L1,PD L1 Costimulatory Protein,PD L1 Protein

Related Publications

Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
April 2017, Nature reviews. Endocrinology,
Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
April 2018, Nature reviews. Clinical oncology,
Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
March 2018, Science (New York, N.Y.),
Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
January 2006, Advances in immunology,
Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
March 2019, Annual review of cancer biology,
Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
January 2020, Science (New York, N.Y.),
Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
October 2015, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
March 2015, Journal of the National Cancer Institute,
Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
June 2022, Life science alliance,
Shizhen Geng, and Tingting Xiang, and Yunya Zhang, and Pengke Guo, and Hongling Zhang, and Zhenzhong Zhang, and Mengchao Gu, and Kaixiang Zhang, and Haiwei Song, and Jinjin Shi, and Junjie Liu
August 2017, Drug discovery today,
Copied contents to your clipboard!